Hodgkin Disease
"Hodgkin Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Descriptor ID |
D006689
|
MeSH Number(s) |
C04.557.386.355 C15.604.515.569.355 C20.683.515.761.355
|
Concept/Terms |
Hodgkin Disease- Hodgkin Disease
- Disease, Hodgkin
- Granuloma, Hodgkin's
- Hodgkin's Granuloma
- Granuloma, Hodgkins
- Hodgkins Granuloma
- Lymphogranuloma, Malignant
- Lymphogranulomas, Malignant
- Malignant Lymphogranuloma
- Malignant Lymphogranulomas
- Hodgkin Lymphoma
- Lymphoma, Hodgkin
- Hodgkin's Disease
- Disease, Hodgkin's
- Hodgkin's Lymphoma
- Hodgkins Lymphoma
- Lymphoma, Hodgkin's
- Hodgkins Disease
- Disease, Hodgkins
- Granuloma, Hodgkin
- Hodgkin Granuloma
- Granuloma, Malignant
- Malignant Granuloma
- Malignant Granulomas
|
Below are MeSH descriptors whose meaning is more general than "Hodgkin Disease".
Below are MeSH descriptors whose meaning is more specific than "Hodgkin Disease".
This graph shows the total number of publications written about "Hodgkin Disease" by people in this website by year, and whether "Hodgkin Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 1 | 0 | 1 | 1995 | 2 | 0 | 2 | 1997 | 2 | 1 | 3 | 1998 | 1 | 0 | 1 | 2001 | 2 | 0 | 2 | 2003 | 1 | 0 | 1 | 2004 | 1 | 0 | 1 | 2005 | 1 | 1 | 2 | 2007 | 1 | 0 | 1 | 2008 | 2 | 0 | 2 | 2009 | 1 | 0 | 1 | 2010 | 1 | 0 | 1 | 2011 | 1 | 0 | 1 | 2014 | 2 | 0 | 2 | 2015 | 5 | 1 | 6 | 2016 | 10 | 0 | 10 | 2017 | 11 | 0 | 11 | 2018 | 11 | 0 | 11 | 2019 | 3 | 0 | 3 | 2020 | 10 | 1 | 11 | 2021 | 7 | 1 | 8 | 2022 | 2 | 0 | 2 | 2023 | 6 | 0 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Hodgkin Disease" by people in Profiles.
-
Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv. 2023 Nov 14; 7(21):6630-6638.
-
Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica. 2023 11 01; 108(11):3025-3032.
-
Lo AC, Lee I, Pei Q, Wu Y, McCarten KM, Hoppe BS, Hodgson DC, Roberts K, Milgrom S, Kessel S, Cole PD, Kelly KM, Cho SY. Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831. Pediatr Blood Cancer. 2023 Aug; 70(8):e30452.
-
Fraley CE, McKinney C, Nuss R, Franklin ARK. Therapy Selection for Hodgkin Lymphoma in Sickle Cell Disease: balancing risks and benefits. Blood Adv. 2023 05 23; 7(10):2042-2046.
-
Mailhot Vega RB, Harker-Murray PD, Forlenza CJ, Cole P, Kelly KM, Milgrom SA, Parikh RR, Hodgson DC, Castellino SM, Kahn J, Roberts KB, Constine LS, Hoppe BS. Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2023 10 01; 117(2):400-403.
-
Milgrom SA, Kim J, Pei Q, Lee I, Hoppe BS, Wu Y, Hodgson D, Kessel S, McCarten KM, Roberts K, Lo AC, Cole PD, Kelly KM, Cho SY. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. Br J Haematol. 2023 06; 201(6):1192-1199.
-
Major A, Kline J, Karrison TG, Fishkin PAS, Kimball AS, Petrich AM, Nattam S, Rao K, Sleckman BG, Cohen K, Besien KV, Rapoport AP, Smith SM. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
-
Lo AC, Major A, Super L, Appel B, Shankar A, Constine LS, Marks LJ, Kelly KM, Metzger ML, Buhtoiarov IN, Mauz-K?rholz C, Costa ARS, Binkley MS, Flerlage J. Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW). Leuk Lymphoma. 2022 08; 63(8):1997-2000.
-
Kleinschmidt-DeMasters BK, Marshall CB, Cykowski MD. Paraneoplastic Lower Motor Neuron Disease. J Neuropathol Exp Neurol. 2021 12 29; 80(12):1125-1127.
-
Forlenza CJ, Gulati N, Mauguen A, Absalon MJ, Castellino SM, Franklin A, Keller FG, Shukla N. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Adv. 2021 12 28; 5(24):5519-5524.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|